Bolus Administration Further Enhances Role of Thrombolytics
Bolus Administration Further Enhances Role of Thrombolytics
Thrombolytic therapy is a routine approach to management of acute myocardial infarction (AMI). The continued modification of thrombolytic therapies aims to provide agents which are fibrin-specific, have a long half-life and are non-immunogenic, ultimately providing more effective and better tolerated thrombolysis.
While no single agent yet has the ideal mix of desirable features, some of the newer agents may be given by bolus administration and have enhanced fibrin-specificity. The ease of bolus administration offers the exciting possibility of administration outside the hospital setting, achieving more rapid reperfusion and theoretically providing mortality advantages. The enhanced fibrin specificity may result in an improved tolerability profile.
Newer adjuvant therapies, in particular the glycoprotein IIa/IIIb inhibitors, offer another pathway to achieve improved clinical outcomes with thrombolytic therapy.
Thrombolytic therapy is a routine approach to management of acute myocardial infarction (AMI). The continued modification of thrombolytic therapies aims to provide agents which are fibrin-specific, have a long half-life and are non-immunogenic, ultimately providing more effective and better tolerated thrombolysis.
While no single agent yet has the ideal mix of desirable features, some of the newer agents may be given by bolus administration and have enhanced fibrin-specificity. The ease of bolus administration offers the exciting possibility of administration outside the hospital setting, achieving more rapid reperfusion and theoretically providing mortality advantages. The enhanced fibrin specificity may result in an improved tolerability profile.
Newer adjuvant therapies, in particular the glycoprotein IIa/IIIb inhibitors, offer another pathway to achieve improved clinical outcomes with thrombolytic therapy.